Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (m-CRC)

7^th Global Summit on Cancer Therapy

October 05-07, 2015 Dubai, UAE

Sherif Abdelwahab

Ain Shams University, Egypt

Posters-Accepted Abstracts: J Cancer Sci Ther

Abstract :

Purpose: This study was conducted to test the efficacy and toxicity of cetuximab and irinotecan as a biweekly regimen in treatment of elderly patients with metastatic colorectal cancer (m-CRC). Patients & Methods: 49 elderly patients (�¢���¥65 years) with m-CRC who progressed after at least one previous line of treatment were enrolled into this study from May 2008 to January 2011. All recruited patients received cetuximab 500 mg/m2 and irinotecan 180 mg/m2 every 2 weeks. Results: 37 patients (76%) were men and 76% of patients had colonic cancer in origin. Median age was 69 years. Median overall survival time was 7 months and median progression-free survival was 4 months. Grade 3-4 skin rash occurred in 20% of patients, grade 3-4 diarrhea in 18% of patients and neutropenia in 28% of patients. Conclusion: Cetuximab combined with irinotecan when administered biweekly is safe and effective for treatment of pretreated elderly patients with m-CRC.

Biography :

Email: sherifok69@hotmail.com